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Impaired metabolic response to recombinant insulin-like growth
factor-i in dialysis patients
DENIS FOUQUE,1 5us C. PENG, and JOEL D. KOPPLE
Department of Medicine, Harbor-UCLA Medical Center, Torrance, and the UCLA Schools of Medicine and Public Health, Los Angeles, California, USA
Impaired metabolic response to recombinant insulin-like growth factor
1 in dialysis patients. The acute metabolic effects of recombinant human
insulin-like growth factor-i (rhIGF-1) were studied after an overnight fast
in six maintenance hemodialysis (MHD) patients, six chronic peritoneal
dialysis (PD) patients and six normal subjects. Each subject received a
subcutaneous injection of rhIGF-1, 50 or 100 sg/kg body wt, given in
random order on two occasions separated by 7 to 21 days. After the
rhIGF-1 injection, plasma insulin, C-peptide, cortisol, amino acids and
glucose decreased. The magnitude of the decrease was greater with the
larger rhIGF-1 dose. The fall in plasma insulin, C-peptide and many
amino acid concentrations was less and the decrease in glucose was similar
in the MHD and CAPD patients as compared to normals. With 50 g
rhIGF-1/kg, plasma insulin and C-peptide decreased more quickly and
often to a greater magnitude in normal individuals. With 100 g rhIGF-
1/kg, the decrease in plasma insulin, C-peptide and amino acids in the
MHD and CAPD patients was almost as frequent as in the normal
subjects, but the magnitude of the fall was often significantly less. This
impaired response occurred in both MHD and CAPD patients even
though, with the 100 j.tg rhIGF-1/kg dose, their plasma IGF-1 was
significantly higher than in normals during most of the first four hours
after injection. These results provide the first in vivo evidence for
resistance to the metabolic effects of rhIGF-1 in patients with advanced
renal failure.
Insulin-like growth factor 1 (IGF-1) is a hormone with a
molecular weight of 7650 that has broad anabolic actions [1]. With
the development of recombinant DNA biosynthesis technology,
sufficient amounts of recombinant human IGF-1 (rhIGF-1) have
been produced to allow it to be administered to humans. RhIGF-1
has now been given experimentally to individuals with a variety of
clinical conditions, including chronic renal failure, where it has
been administered primarily to investigate its effects on plasma
levels of glucose and other hormones, anabolism, and renal
function [2—4].
Several in vitro studies suggest that patients with renal failure
may be resistant to the actions of IGF-1 [5, 6]. There is evidence
for increased circulating concentrations of some IGF-1 binding
proteins or an elevated serum binding capacity for IGF-1 in
patients with chronic renal failure [7—91. Other studies have
obtained evidence for increased inhibition of the actions of IGF-1
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(or somatomedin C) in serum of patients with chronic renal
failure [5, 6]. At least some of these circulating inhibitors are
probably of small molecular weight (such as, under 1000 daltons)
because hemodialysis treatment temporarily increases bioactivity
of IGF-1.
There are no studies examining whether the actions of IGF-1
are inhibited in vivo in patients with renal failure. We recently
investigated the pharmacokinetics of rhIGF-1 in normal individ-
uals and patients undergoing maintenance hemodialysis (MHD)
or continuous ambulatory peritoneal dialysis (CAPD) [101. This
study offered us the opportunity to examine, at the same time, the
acute effects of rhIGF-1 on plasma glucose and amino acid
concentrations and serum levels of certain regulatory hormones.
The results of this investigation provide the first in vivo data
indicating that patients with chronic renal failure are resistant to
the actions of rhIGF-1.
Methods
Patients
Studies were carried out in six MHD patients (ages 41.5 4.7
(SEM) years), six CAPD patients (43.5 5.1 years) and six
normal adults (35.8 6.7 years). These individuals participated in
a pharmacokinetic study of serum IGF-1 levels in which they
received a single subcutaneous injection of rhIGF-1 on two
occasions [101. Characteristics of the patients are described in this
previous paper [10] and also in Table 1. All subjects were clinically
stable. Age, body weight, relative body weight and percent body
fat were not different among the three groups. One woman was
present in each group. MHD patients had undergone hemodial-
ysis for 46.6 17.6 months prior to the study. CAPD patients had
received peritoneal dialysis for 12.8 4.0 months before the
study.
Prior to this study, the normal individuals had been receiving no
medicines; the dialysis patients generally took only a multivitamin
(Nephrovite®), ferrous sulfate and often antihypertensive medi-
cines. As described in the previous paper [10], with one exception,
no medicines were taken during the course of this study. This
protocol was approved by the Harbor-UCLA Medical Center
Human Subjects Committee. Informed written consent was ob-
tamed from all subjects.
Protocol design
MilD patients were admitted to the Clinical Research Center
(CRC) at Harbor-UCLA Medical Center immediately after a
routine hemodialysis treatment the day before the study. CAPD
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Table 1. Characteristics of the subjects
Hemodialysis CAPD Normal
Age years 41.5 4.7 43.5 5.1 35.8 6.7
SUN mgldL 50.3 6.6 61.7 7,1b 13.2 0.9
5Cr mg/dl 10.9 i.ia 13.9 0.9 0.1
Body weight kg 71.5 5•9a 71.5 8,2b 63.4 4.8
RBW % 96.6 6.9 95.4 5.1 93.5 4.8
Body fat % 22.3 2.3° 23,9 1,9b 21.3 2.5
Values are expressed as mean SEM. Abbreviations are: SUN, serum
urea nitrogen; 5Cr' serum creatinine; RBW, relative body weight, calcu-
lated from the NHANES data [11].
a Obtained about 13 to 18 hr after the end of the last hemodialysis
treatment
b Obtained after emptying the peritoneal cavity, the morning of the test
patients and normals individuals also entered the CRC the day
before the study. All subjects were fasted from 10 p.m. the night
that they entered the CRC until after the 240 minute blood
sample was drawn at about 12:00 p.m. the next day. Normal
subjects only were allowed to drink up to 500 ml of deionized
water between 10:00 p.m. and 8:00 a.m. to compensate for urine
losses. The CAPD patients infused dialysate containing 1.5%
dextrose for the overnight dwell before the study. They drained
the dialysate at 7:00 a.m. the following morning and did not
reinfuse dialysate until after the 240 minute blood drawing. At
approximately 8:00 a.m. the next morning, all subjects were given
one subcutaneous injection of either 50 or 100 pg/kg body wt of
rhIGF-1 in the right or left lower quadrant of the abdominal wall.
They were readmitted to the CRC within 7 to 21 days to receive
the second dose of rhIGF-1 in an identical protocol; the order of
the administration of the two doses was determined randomly.
At about 7:45 a.m., a sterile 22-gauge butterfly needle was
inserted into a peripheral arm vein and kept there for the duration
of the study. After each blood drawing, the needle and attached
tubing were rinsed with heparinized saline. For the present study,
blood samples were obtained at 5 minutes before the rhIGF-1
injection and at 60, 120, 180 and 240 minutes afterwards. Blood
was drawn in glass tubes, immediately placed on ice. The blood
was quickly centrifuged at 2500 g for 15 minutes at 4°C. Except for
amino acids, the supernatant plasma was pipetted and immedi-
ately frozen at —20°C in polyethylene tubes until measurement.
RhIGF-1 was obtained from Ciba-Geigy Corp. (courtesy of Dr.
H.P. Guler), stored, and prepared for injection as previously
described [10].
Assays
Blood was drawn in glass tubes containing heparin for measure-
ment of plasma amino acids, insulin, glucose, cortisol and growth
hormone, and trasylol for determination of C-peptide and gluca-
gon. For amino acid measurements, which were performed on the
baseline and 240 minute blood specimens, 1.0 ml of plasma was
deproteinized by addition of 0.1 ml of 45% (wt/vol) sulfosalicylic
acid; the tube was then agitated for one minute with a Vortex
mixer. After standing for 10 minutes, the deproteinized sample
was centrifuged at 12,000 X g in a microcentrifuge (Fisher
Scientific, Springfield, NJ, USA), and the protein-free superna-
tant was removed and stored at —70°C until analysis. The
supernatant was analyzed with a Beckman Model 6300 Amino
Acid Analyzer (Beckman Instruments, Palo Alto, CA, USA).
Insulin was measured by ultrasensitive RIA using a polyclonal
guinea-pig antibody (ICN, Inc.), that detects values as low as 7
pmollliter (1 U/ml). For insulin, the intra- and interassay
variability was 4.5% and 11.2%, respectively. Glucose was mea-
sured with the Abbott VP Autoanalyser using the hexokinase
reaction. Intra- and interassay variabilities were 1% and 1.4%,
respectively. Cortisol was measured by RIA using a polyclonal
rabbit antibody (ICN, Inc.). Glucagon was measured by RIA using
a 30 k polyclonal rabbit antibody (courtesy of Dr. Unger). The
intra- and interassay coefficient of variation was 7.2% and 16.6%,
respectively. C-peptide was determined by RIA against a poly-
clonal goat antibody (courtesy of Eli Lilly, Inc.). The intra- and
interassay coefficient of variation was 5.0% and 12.9%, respec-
tively. Human growth hormone was measured by RIA with a
standard double antibody using a polyclonal rabbit antibody
developed in house. The intra- and interassay coefficient of
variation was 9.4% and 8.9%, respectively.
Calculations of plasma total essential, total nonessential and
total amino acids were calculated as follows: total essential amino
acids were equal to the sum of histidine, isoleucine, leucine,
lysine, methionine, phenylalanine, threonine and valine. Total
nonessential amino acids were calculated as the sum of alanine,
arginine, asparagine, glycine, glutamic acid + glutamine, orni-
thine, proline, serine and taurine. Total amino acids were calcu-
lated as the sum of total essential amino acids, total nonessential
amino acids, cystine and tyrosine. Because of space limitations,
many measurements that were made at hourly intervals are
reported here at less frequent intervals (Table 3); in every case,
the hourly measurements are consistent with the results shown in
this manuscript.
Statistical analysis
Values are given as the mean standard error of the mean
(sEM). Two-way analyses of variance, with "group" as a between
subjects effect and "time" as a repeated measure with interaction,
were performed to compare the overall mean levels and temporal
responses between groups. When a group-by-time interaction was
found to be significant, a factorial measure analysis of variance
comparing groups only was done for each period of time. When a
time-effect was found significant, the paired two-tail Student's
t-test was performed to compare the post-injection serum concen-
trations with the baseline values within each group. To determine
if there was a dose effect, an analysis of variance with repeated
measures was performed to compare the results from the two
doses within the same group. Significance was taken as P < 0.05
as indicated.
Results
Baseline insulin values were not different among the three groups
before the injection of either dose of rhIGF-1 (Fig. 1). Within one
hour after administration of the 50 p.gfkg dose, plasma insulin
appeared to begin to fall in the CAPD patients and normal
subjects. Plasma insulin was significantly lower than baseline at
120, 180 and 240 minutes after the injection in both the CAPD
patients and normal individuals (Fig. 1). There was no change in
plasma insulin in the MHD patients, and the plasma values in
these individuals were greater than in normals at 180 and 240
minutes and were higher than in CAPD patients at 240 minutes
after the injection. With the 100 g rhIGF-lIkg dose, plasma
insulin decreased more rapidly, and in every group (Figs. 1 and 2).
Plasma insulin was significantly less than baseline values at 60,
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A (Table 2). With the 100 j.g rhIGF-1/kg dose, plasma C-peptide
fell significantly in all three groups. The percentage decrements
from baseline values in plasma C-peptide concentrations four
hours after the rhIGF-1 injection in normal, MHD and CAPD
individuals were 60 4 (sEM), 33 7 and 30 6% with the 50 g
rhlGF-1/kg dose and 87 3, 30 7 and 41 8% with the 100 g
ti] rhIGF-1 dose (difference from normal subjects with the 50 pg/kg
dose: MHD patients, P < 0.025; CAPD patients, P < 0.005;
difference with the 100 pg/kg dose: MHD patients, P < 0.001;
** CAPD patients, P < 0.001).
With the 50 g rhIGF-1/kg dose, plasma glucose decreased
significantly in the normal subjects and MHD patients, but not in
the CAPD patients (Table 3). With the 100 tg rhIGF-1/kg dose,
plasma glucose also fell in all three groups of subjects. There was
no difference in plasma glucose at any given time point among the
three groups. After the 100 ig rhIGF-1/kg dose, plasma glucose
was significantly reduced in all three groups of individuals only at
180 minutes (data not shown). The fall in plasma glucose levels
was not large in any group with either dose of rhIGF-1. At four
hours after the injection, the decrease in plasma glucose in the
three groups averaged one to 13 mgldl with the 50 .tg rhIGF-1/kg
dose and 11 to 17 mgldl with the 100 .tg rhIGF-1/kg dose.
Plasma glucagon concentrations were greater than normal
before administering the 50 g rhIGF-1/kg dose in both the MHD
and CAPD patients (Table 3). In the MHD and CAPD patients,
plasma glucagon was also greater than normal at two and four
hours after the rhIGF-1 dose. Plasma glucagon fell significantly
only in the MHD patients at four hours after the 50 g rhIGF-
1/kg dose. There were no changes between the three groups of
;**t patients in plasma glucagon levels before or after injection with
* * t 100
.tg rhIGF-1/kg. Also, plasma glucagon did not change signif-
icantly in any group after the 100 jg rhIGF-1/kg dose. Plasma
cortisol fell significantly in all three groups with each dose of
__________________________________________
rhIGF-1 dose (Table 3). There was no significant difference
between plasma cortisol levels in the three groups at any time
point. Plasma growth hormone levels did not change significantly
during the study and were not different between the three groups
with either rhIGF-1 dose.
Fasting plasma essential, nonessential and total amino acids
and the changes in plasma amino acids between baseline and the
four hour blood sampling are shown in Table 4 and Figures 3 and
4. In the CAPD patients, baseline plasma total essential amino
acids tended to be lower as compared to the normal values before
either rhIGF-1 dose was given, and were also less than the MHD
patients before the 50 .tg rhIGF-1/kg dose (Table 4). Baseline
plasma total nonessential and total amino acids did not differ
among the three groups. Four hours after the injection of the 50
g rhIGF-lIkg dose, there was a tendency for many individual
plasma amino acids to decrease, particularly in the normal
subjects. There were 11 plasma amino acids that fell significantly
in the normal subjects, whereas only five plasma amino acids
decreased in the CAPD patients and one amino acid fell in the
MHD patients (Fig. 3). Plasma total essential, total nonessential
and total amino acids fell significantly at four hours after injection
in both the normal individuals and the CAPD patients, but not in
the MHD patients (Table 4). There was no difference in the
decrement in the sums of these amino acids between the three
groups. After the 50 g rhIGF-1/kg dose, there was a significantly
greater decrement in plasma alanine and proline in the normal
individuals than in either the MHD or the CAPD patients (Fig. 3).
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Fig. 1. Plasma insulin concentrations immediately before and at hourly
intervals for four hours after a subcutaneous injection of rhIGF-1, 50 (A) or
100 (B) 1ug/kg body wt, in normal individuals (•), CAPDpatients (0), and
maintenance hemodialyis (tx) patients. Values indicate mean SEM. Differs
from baseline values, p < 0.05; **JJ < 0,01. Differs from normal subjects,
tP < 0.05. Differs from CAPD patients, ¶P < 0.05. N = 6 in each group.
120, 180 and 240 minutes in normal subjects, at 120, 180 and 240
minutes in CAPD patients and at 180 and 240 minutes in MHD
patients. Plasma insulin was also greater in one or both groups of
dialysis patients as compared to normal subjects at 120, 180 and
240 minutes. The percentage fall in plasma insulin was greater in
the normal subjects as compared to the MHD or CAPD patients
at a number of time points after the injection of either dose of
rhIGF-1 (Fig. 2). There was no difference in the decrement in
plasma insulin between the MHD versus CAPD patients with the
100 g rhIGF-1/kg dose.
Baseline plasma C-peptide was significantly elevated in the
MHD and CAPD patients as compared to the normal individuals,
as has been previously reported [12] (Table 2). The plasma
C-peptide values fell significantly in the MHD and CAPD patients
and the normal individuals given the 50 jg rhIGF-1/kg dose
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Time, minutes Time, minutes
Fig. 2. The percent change (decrement) in plasma insulin concentrations at hourly intervals after the injections of rhJGF-1, 50 (A) or 100 (B) ,uglkg in normal
individuals (fl), CAPD patients (), and maintenance hemodialysis patients (R). Values at each time point represent the percent difference between the
plasma insulin at that time and the baseline levels. Data indicate mean 5EM. S, indicates that the change from baseline is different from zero, P <
0.01. N, indicates that there was no statistically significant change from baseline. *The magnitude of the decrement is significantly less than in normal
subjects, P C 0.05. N = 6 in each group.
Table 2. Plasma C-peptide levels after a single subcutaneous injection of rhIGF-1
rhIGF-i 50 jig/kg body wt rhIGF-1 100 jig/kg body wt
Time 0 lhr 2hr 3hr 4hr 0 lhr 2hr 3hr 4hr
Normal 0.5±0.1 0.3±0.IC 0.3±0.1° a2±oja O.2±0.0 0.4±0.1 0101b o.i±o.oh o.i±o.ob 0.i±0.0
MHD 2.0 0.4° 1.8 0.4° 1.7 0.4° 1.6 0.3CC 1.3 O.2a 2.1 0.4° 1.9 0.4° 1.8 0.4'° 1.8 0,4be 1.6
CAPD 1.4 01d 1.3 0.1° 1.2 0.1C 1.2 or 1.0 01hd 1.9 0.2° 1.6 o.2 1.5 02ad 1.3 0.2 1.0 o.lae
Values are expressed as jig/liter, mean 5EM.
Differs from Baseline, C P C 0.05, b P C 0.01, C P C 0.001
Differs from normal values obtained at the same time, ci P C QQ5, P C 0.01
Arginine also decreased more in the normal subjects than in the
MHD patients.
With the 100 jig rhIGF-1/kg dose, most individual plasma
amino acids fell significantly in all groups, although there was a
greater tendency for the amino acids to decrease in the normals
(Fig. 4). At four hours after the injection, 17 plasma amino acids
were decreased in the normal subjects, 13 in the CAPD patients
and 16 in the MHD patients. The plasma total essential, total
nonessential and total amino acids decreased in each group
(Table 4). However, there was a significantly greater fall in plasma
total essential amino acids, total nonessential amino acids and
total amino acids in the normal subjects than in either the MHD
and CAPD patients. Also, the decrease in many individual plasma
amino acids was significantly greater in normal subjects than in
either group of dialysis patients (Fig. 4). This greater fall in
plasma amino acids in the normal subjects as compared to both
MHD and CAPD patients was observed for isoleucine, phenylal-
anine, threonine, arginine, and proline. The decline in plasma
leucine was greater in normals than in MHD patients. Plasma
alanine and glycine decreased more in normal subjects than in
CAPD patients. Only plasma glycine fell more in MHD than in
CAPD patients.
Discussion
This investigation was carried out because in vitro studies of
IGF-1 (formerly called somatomedin C) bioactivity indicated that
there is resistance to the actions of serum IGF-1 in both children
and adults with advanced renal failure [5, 6]. Moreover, there is an
inverse relationship between the magnitude of renal failure and
the degree of inhibition of IGF-1 [6]. IGF-1 has strong anabolic
actions. Since approximately 40% of maintenance dialysis patients
are malnourished [13, 14], the question of a resistance to the
actions of IGF-1 may be clinically relevant.
The results of this study indicate that injection of rhIGF-1
causes a decrease in plasma insulin, C-peptide, cortisol, many
amino acids and glucose. The magnitude of the fall in these
compounds tended to be greater at the higher (100 jig/kg) dose of
rhIGF-1. Moreover, the rhIGF-1 stimulated fall in plasma insulin,
C-peptide and many amino acids was reduced in the MHD and
CAPD patients. The abnormalities in the response to rhIGF-1 in
A B
NNN SNN SNN SNS SSN SSN SSS SSS
-0%
—20% f —20%
=
CoC
'U
E
-40%
- -40%a
C
—60% 2 —60%
C
—80%
60 120 160 240 60 120 180 240
880 Fouque et aL Resistance to rhIGF-1 in dialysis patients
Table 3. Plasma glucose and hormone levels after a single subcutaneous injection of rhIGF-1
rhIGF-1 50 pg/kg body wt rhIGF-1 100 sgfkg body wt
0 2 hr 4 hrTime 0 2 hr 4 hr
Glucose mg/dl
Normal 104 3 98 4 93 4 99 3 81 8 82
MHD 105±5 100±2 93±la 101±5 92±3 86±3
CAPD 94±1 93±1 93±2 94±2 87±2a 83±4a
Glucagon ng/liter
Normal 265 79 224 69 198 44 311 90 444 165 339 84
MMD 923 84C 753 155C 569 101"° 524 102 550 157 548 103
CAPD 1055 294C 1340 321C 884 202C 929 353 896 273 978 284
Cortisol j.g/dl
Normal 14.6 1.8 8.4 1.7 7.2 1.la 13.7 1.4 9.4 1.7 6.0 0.8
MHD 10.3 1.5 2.3 1.1 6.7 0.7 9.6 0.3 6.3 1.oa 6.9 1.2
CAPD 10.3 1.7 6.5 O.6 5.4 1.4 9.6 0.8 6.2 0.6a 6.2 1.2
Growth hormone j.tg/liter
Normal 0.5 0.3 0.3 0.1 1.2 1.0 0.4 0.1 2.3 1.8 0.4 0.1
MHD 1.9 0.6 0.9 0.3 0.4 0.1 1.0 0.2 0.8 0.2 0.6 0.2
CAPD 2.2 0.8 0.5 0.1 0.8 0.2 1.0 0.2 1.0 0.4 1.1 0.8
Data are mean SEM
Differs from Baseline, P < 0.05, b P < 0.01
Differs from normal values obtained at the same time, c P < 0.05
Table 4. Plasma amino acids
Baseline fasting values smolIliter % Change in amino acids at 4 hr
Normal MHD CAPD Normal MHD CAPD
Total essential amino acids
rhIGF-1, 50 jtg/kg 997 29 954 72 738 45"
rhIGF-1, 100 rg/kg 1062 50 983 75 807 68
—19.6 4.9 —7.7 7.6 —14.0 3.4
—31.4 2.6 —21.5 l.5 —20.5 2•3cf
Total nonessential amino acids
rhIGF-1, 50 rg/kg 1758 93 2098 200 2101 191
rhIGF-1, 100 .rg/kg 1816 106 2023 185 2156 154
—23.1 5.8e —9.7 6.0 —12.9
—29.5 2.2 —19.9 l.1' —17.8 3•0cf
Total amino acids
rhIGF-1, 50 sg/kg 2754 113 3051 267 2838 196
rhIGF-1, 100 jsg/kg 2877 147 3006 245 2963 182
—21.9 54a —9.1 6.5 —13.3 2.6
—30.2 2.3 —20.4 0.9 —18.5 2.7
Values are mean SEM. Essential amino acids are the sum of histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine and valine.
Nonessential amino acids are the sum of arginine, asparagine, glycine, glutamic acid and glutamine, ornithine, proline, serine and taurine. Total amino
acids are the sum of the essential plus nonessential amino acids, cystine and tyrosine.
Different from normals: a P < 0.05, bp < 0.01, P < 0.005
Different from hemodialysis patients: d P < 0.01
Significantly different from zero: P < 0.05, 1P < 0.01
the MHD and CAPD patients depended on the dose of rhIGF-1
administered. At the low rhIGF-1 dose, the MHD and CAPD
patients, in contrast to the normal individuals, tended to show
either no response or a delayed response, particularly with regard
to plasma insulin, C-peptide and amino acids. With the higher
rhIGF-1 dose (100 ig!kg) these patients, as with the normal
subjects, often displayed a reduction in plasma levels of these
compounds, but the magnitude of the fall not infrequently was
significantly less than in the normal individuals. The reduced
effect of rhIGF-1 in the chronic dialysis patients is even more
striking if the serum IGF-1 levels are considered. Plasma IGF-1
concentrations in the MHD and CAPD patients were significantly
higher than in the normal individuals during the first four hours
after injection of 100 .tg rhIGF-lIkg and also tended to be higher
(P: NS) after the lower dose [10]. These findings provide further
evidence for an in vivo inhibition of the effects of rhIGF-1 in
patients with advanced renal failure.
Although this study was not designed to investigate the mech-
anisms by which rhIGF-1 decreases plasma amino acids and
glucose concentrations, it is likely that these changes reflect an
anabolic response to rhIGF-1. This hormone stimulates protein
synthesis and reduces protein catabolism [15]. This effect as well
as a possible stimulation of the intracellular movement of amino
acids by rhIGF-1 may account for the fall in plasma amino acids.
RhIGF-1 is known to suppress plasma insulin in normal sub-
jects [16, 17]. RhIGF-1 directly decreases secretion of insulin by
the pancreas of normal rats [18]. Hence, the impaired decline in
plasma insulin in the MHD and CAPD patients most likely
reflects a decreased suppression of pancreatic insulin secretion.
The metabolic clearance of insulin is reported to be moderately
reduced (10%) or not different from normal adults [19—211. After
initiating maintenance dialysis treatment, insulin clearance is
reported to be similar to that of normal adults [19, 20]. In any
event, the plasma insulin half-life is quite short, 6 to 8 minutes in
normal adults. Thus, the reduced or delayed fall in plasma insulin
in both MHD and CAPD patients after receiving rhIGF-1 appears
to be due to a reduced inhibitory effect of rhIGF-1 on pancreatic
insulin secretion rather than to impaired plasma insulin clearance.
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Plasma nonessential amino acids
The impaired fall in C-peptide in the MHD and CAPD is
subject to a similar interpretation. Although impaired plasma
clearance of C-peptide may have contributed to the reduced fall in
C-peptide, in the dialysis patients, it is likely that decreased
suppression of pancreatic insulin secretion by rhIGF-1 played the
more important role. The plasma half-life of C-peptide is reported
to be 36 minutes in normal adults [12]. Blackman and colleagues
reported a 50% increase in C-peptide half-life and a 30%
decrease in C-peptide clearance in six kidney transplant recipients
with moderately reduced creatinine clearance [12]. Therefore, the
fact that, in MHD and CAPD patients, C-peptide decreases
significantly three to four hours after rhIGF-1 administration
most likely reflects a substantial reduction in C-pcptide secretion.
Taken together, the significant decrease in plasma insulin and
C-peptide concentrations shortly after the rhIGF-1 injection
strongly suggest direct rhIGF-1 inhibition of pancreatic secretion,
which is less potent in maintenance dialysis patients than in
normal adults.
The fall in plasma glucagon that occurred only after the 50 tg
Fig. 3. The percent change (decrease) in plasma
essential (A) and nonessential (B) amino acids
between baseline and 240 minutes after a
subcutaneous injection of rhIGF-1, 50 pg/kg body
weight, in notmal individuals (D), CAPD patients(), and maintenance hemodialysis () patients.
Total essential amino acids are calculated as
the sum of all eight essential amino acids as
indicated in Table 3, but not cystine and
tyrosine. Change in plasma amino acids: differs
from zero, S, P < 0.01; N, not different from
zero (P > 0.01). Differs from normal
individuals, *p < 0.05; tP < 0.01.
N = 6 in each group.
rhIGF-I/kg dose in the MHD patients is puzzling. Guler, Zapf
and Froesch [16] found an increase in plasma glucagon after an
intravenous bolus of 100 .tg rhIGF-1/kg in normal individuals, in
response to an acute drop in plasma glucose (35 mg/dl). Mauras,
Horber and Haymond [22] reported a decrease in plasma gluca-
gon in normal individuals after a continuous intravenous infusion
of a low rhIGF-1 dose (5 or 10 tg/kg). No hypoglycemia occurred
in this latter study. Higher plasma glucagon concentrations in
chronic renal failure patients are well described [23]. These
elevated glucagon levels are largely, but not entirely, due to
inactive moieties [23]. It is therefore difficult to interpret plasma
glucagon levels in these individuals without extensive fraction-
ation studies.
It is intriguing that plasma glucose concentrations decreased
similarly in all three study groups after each dose of rhIGF-1
(Table 3). The fall in plasma glucose may reflect both increased
intracellular transport of glucose, particularly into muscle, as well
as suppressed hepatic glucose production. In preliminary studies
in one MHD patient, we observed that the suppression of glucose
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synthesis after an intravenous infusion of rhIGF-1 was similar to
that of normal individuals (unpublished observations). Resistance
to insulin-induced peripheral uptake of glucose in renal failure is
well established [20]. Our findings that plasma glucose fell simi-
larly in all three groups of subjects after either rhIGF-1 injection
raises the possibility that the uremia does not induce resistance to
rhIGF-1-stimulated peripheral glucose uptake. Intensive dialysis
therapy also might reduce resistance to IGF-1, as it has been
reported to do for insulin [19, 21].
There are several likely causes for the impaired actions of
rhIGF-1 in the MHD and CAPD patients. Increased levels of
plasma inhibitors of rhIGF-1 are well described in renal failure
patients [5—8]. Although some of these inhibitory factors appear
to be of sufficiently small size to be dialyzable [5], others are
probably proteins or protein fragments. Indeed some of these
compounds may be IGF-1 binding proteins or protein fragments
that are present in increased concentrations in uremic plasma [8].
The finding that after injection of 100 g rhIGF-1/kg the plasma
concentrations rose higher and the volume of distribution of
IGF-1 was less in the MHD and CAPD patients is consistant with
Fig. 4. The percent change (decrease) in plasma
essential (A) and nonessential (B) amino acids
between baseline and 240 minutes after a
subcutaneous injection of rhIGF-1, 100 pg/kg
body weight, in normal individuals, CAPD
patients and maintenance hemodialysis patients.
Change in plasma amino acids: differs from
zero, S, P < 0.01; N, not different from zero (P
> 0.01). Differs from normal individuals,
0.05; tP < 0.01. Differs from hemodialysis
patients, ¶P < 0.05. N = 6 in each group.
the possibility that the rhIGF-1 bound to increased concentrations
of plasma proteins [10]. These proteins may have been normally
occurring IGF-1 binding proteins. Increased protein binding may
have temporarily decreased the availability of rhIGF-1 for bioac-
tivity on tissues. Alternatively, resistance to rhIGF-1 could also
occur at the cellular level. Recently, Ding et a! found a postre-
ceptor defect to rhIGF-1 actions in epitrochlearis muscle of rats
with chronic renal failure as compared to sham-operated, pair-fed
controls [24].
The impaired decline in plasma amino acids to rhIGF-1 may
reduce the availability of intracellular amino acids for anabolic
processes and may be a cause of the altered intracellular amino
acid pools described in uremic patients [25]. Alternatively, this
impaired response may reflect a reduction in the normal anabolic
response to the rhIGF-1 injection [15]. Moreover, the altered
response of both plasma insulin and amino acids to rhIGF-1 in
dialysis patients might be part of a more general resistance to the
effects of rhIGF-1 in advanced renal failure [24].
It is important to emphasize that the present study lasted only
four hours, and it is possible that the impairment in the actions of
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rhIGF-1 in the MHD and CAPD patients abates after several
hours. This would be consistent with the rapid fall in plasma
IGF-1 levels and presumably greater tissue distribution of IGF-1
after the first four hours post-injection [10]. Ding, Gao and
Kopple found resistance to the protein anabolic effects of rhIGF-1
in isolated cpitrochlearis muscle from rats with chronic renal
insufficiency [261. However, despite this resistance, rhIGF-1 still
induced a protein anabolic effect in these animals [26]. Peng,
Fouquc and Kopple found that rhIGF-1, 50 or 100 JLg/kg given
subcutaneously every 12 hours, abruptly and markedly increased
nitrogen balance in CAPD patients with protein-calorie malnutri-
tion [4]. Thus, resistance to rhlGF-l in MHD and CAPD patients
is partial and can be overcome with sufficient doses of rhIGF-1.
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